Descripción del proyecto
Una prueba de diagnóstico inmediato detecta la resistencia a los antibióticos en la tuberculosis
La farmacorresistencia supone todo un desafío médico en el tratamiento de muchas enfermedades infecciosas, como la tuberculosis, que es responsable de más de un millón y medio de muertes cada año. La prescripción de antibióticos ineficaces agrava la situación y los pacientes deben realizarse cribados para identificar especies bacterianas farmacorresistentes. El objetivo del proyecto mfloDx, financiado con fondos europeos, es desarrollar una prueba diagnóstica de tuberculosis fácil de usar que pueda generar resultados sobre la resistencia a los antibióticos en menos de tres horas. La prueba se puede realizar de inmediato, con formación e instrumental mínimos. Su alta especificidad y sensibilidad, junto con su rentabilidad, lo hacen ideal para su puesta en práctica en países en desarrollo.
Objetivo
Tuberculosis (TB) kills more people than any other pathogen-borne illness; yearly, 10M people fall ill and 1.6M die. TB also contributes to a growing existential crisis: the spread of antibiotic resistant bacteria. Multi-drug-resistant TB is flourishing due to incomplete diagnoses and widespread prescription of ineffective antibiotics. Commercial diagnostics often require equipment in the €12-70K range and are either very slow or incomplete. As a result, less than one-third of new TB patients undergo strain testing to determine whether antibiotic resistance is present.
mfloDx is a low-cost, DNA-based TB diagnostic, similar to home-pregnancy tests. In <3 h, our test identifies nearly 100% of drug resistant TB strains with 92-97% accuracy, directly from sputum samples and with a minimum of lab equipment or training. Clinical validation is ongoing and we are preparing for in vitro diagnostic (IVD) certification for an estimated launch in late 2022. The low cost, accessibility, and stability of mfloDx tests will enable uptake in developing countries, which are the source of much antibiotic-resistant infection.
EMPE‘s team are experts in TB research, business development, and diagnostic tools for infectious disease. mfloDx grew from a molecular innovation called the Padlock probe, developed by our co-founder, Mats Nilsson. EMPE CEO Pavan Asalapuram combined this technology with a lateral flow biosensor, as a fast and accurate kit to identify antibiotic resistance. EMPE has raised ~€2M in seed capital and started clinical validations with partners in Spain and India. Thus far, our facility at Karolinska Institute Science Park produces test kits for research use only (RUO). EIC funding would accelerate clinical validation of our kits toward in vitro diagnostic certification and enable the implementation of large-scale production. This project will enable us to launch our top-of-the-line product and reach a worldwide €3.5B TB diagnostics market with WHO backing.
Ámbito científico
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensors
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-EIC-SMEInst-2018-2020-3
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
171 65 Stockholm
Suecia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.